Comparison of Two Assays for Molecular Determination of Rifampin Resistance in Clinical Samples from Patients with Buruli Ulcer Disease
Loading...
Date
2014-01-29
Journal Title
Journal ISSN
Volume Title
Publisher
Journal of Clinical Microbiology
Abstract
Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans,
involves the skin, subcutaneous fatty tissue, and bones and
predominantly affects children 15 years of age. If left untreated,
contractures may cause severe functional limitation. Standardized
antimycobacterial treatment consists of rifampin (RMP) and
streptomycin administered for 8 weeks. An oral regimen combiningRMPand
clarithromycin is currently under clinical evaluation
(1–3). Notwithstanding the efficiency of chemotherapy, treatment
failures and various types of secondary lesions have been
reported, suggesting the need for customized clinical management
strategies (4–6).
Description
An article published by Journal of Clinical Microbiology and available doi.org/10.1128
/JCM.03119-13.
Keywords
Citation
Journal of Clinical Microbiology Volume 52 p. 1246–1249